Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

GeneDx Holdings (WGS) Long-Term Debt Repayments (2021 - 2026)

GeneDx Holdings has reported Long-Term Debt Repayments over the past 3 years, most recently at $54.0 million for Q1 2026.

Quarterly Long-Term Debt Repayments changed N/A to $54.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $56.0 million through Mar 2026, up 2700.0% year-over-year, with the annual reading at $3.7 million for FY2021, 7.03% down from the prior year.
Long-Term Debt Repayments was $54.0 million for Q1 2026 at GeneDx Holdings, up from $2.0 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $54.0 million in Q1 2026 and troughed at $2.0 million in Q1 2023.